reading receptor threads from 2024 and half of it aged badly
Something I keep coming back to: reading receptor threads from 2024 and half of it aged badly.
Long half-life in this class comes from structural modification that promotes albumin binding and resists enzymatic degradation. Weekly dosing is a consequence of the molecule, not a convenience decision.
GIP receptor biology is genuinely unsettled — there is a live argument about agonism versus antagonism at the receptor — and the clinical results are robust regardless, which is an uncomfortable and interesting position.
Tolerance to the gastric effect develops with continued exposure while the appetite effect largely persists. That single fact explains most of the "it settles but it still works" pattern the side-effect board reports.
Not medical advice, obviously, and nothing here is approved for human use. One person with a spreadsheet.
best — the order this archive was captured in
Retitled to distinguish preclinical from clinical, which the original ran together.
What does the discussion section say about the limitation you are glossing?
Yes. The central component is the one that explains the reports on this site better than gastric emptying does.
glucagon agonism sounds paradoxical until you read the energy expenditure work
The mental model, in four steps, that makes the rest of this site legible.
One: gut hormones amplify the insulin response to food. Two: agonists at those receptors act peripherally on insulin secretion and gastric emptying, and centrally on appetite. Three: structural modification gives them a long half-life, so exposure is smooth and weekly. Four: tolerance develops to some effects and not to others.
From those four, most of what the experience boards report falls out: why the side effects cluster early, why they settle at a stable dose, why appetite reduction persists, and why the scale and the appetite move on different clocks.
Agreed that receptor distribution is the key to the side-effect map. It is not a mystery, it is anatomy.
Does the effect persist with continued dosing or does tolerance develop?
Correction: that is glucose-dependent insulin secretion, which is why hypoglycaemia risk is low as monotherapy. Not the same claim as you made.
Receptor expression in a tissue is necessary but not sufficient for an effect. You also need the agonist to reach it at relevant exposure, and that is where a lot of confident mechanism talk falls down.
Yes. The discussion section is where the authors say what they actually think, and almost nobody here reads it.
Read the primary paper after arguing about the summary for a fortnight. The discussion section said almost the opposite of what the thread had concluded.
- 1The mental model, in four steps, that makes the rest of this site legible.…6 comments in this branch · started by u/formulary_fighter